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A marked escalation in the rate of discovery of new types of human polyomavirus has occurred over the last
ﬁve years largely owing to recent technological advances in their detection. Among the newly discovered
viruses, Merkel Cell Polyomavirus (MCPyV or MCV) has gained the most attention due to its link with a rare
human cancer. Infection with MCPyV is common in the human population, and the virus is detected in
several anatomical locations, but most frequently in skin. Study of MCPyV molecular virology has been
complicated by the lack of straightforward cell culture models, but recent in vitro studies are making strides
towards understanding the virus life cycle, its cellular tropism, and mode of transmission. While MCPyV
shares several traditional traits with other human polyomaviruses, the burst of research since its discovery
reveals insight into a virus with many unique genetic and mechanistic features. The evidence for a causal link
betweenMCPyV and the rare neuroendocrine cancer, Merkel Cell Carcinoma (MCC), is compelling. A majority
of MCCs contain clonally integrated viral DNA, express viral T antigen transcripts and protein, and exhibit an
addiction to the viral large T and small t antigen oncoproteins. The MCPyV large T antigen contains MCC
tumor-speciﬁc mutations that ablate its replication capacity but preserve its oncogenic functions, and the
small t antigen promotes an environment favorable for cap-dependent translation. The mechanisms of
MCPyV-induced transformation have not been fully elucidated, but the likely etiological role of this new
polyomavirus in human cancer provides a strong opportunity to expand knowledge of virus–host interactions
and viral oncology.
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For over ﬁfty years, study of the Polyomaviridae family of
viruses has yielded signiﬁcant contributions to the understanding
of basic cell biology, cancer biology, and viral oncogenesis. There
are currently three genera and twenty-two different species of
polyomaviruses, all of which are non-enveloped, icosahedral
viruses that contain a circular, double-stranded DNA genome of
approximately 5000 base pairs (Johne et al., 2011). The trans-
forming potential of these viruses has long been appreciated since
isolation of the ﬁrst polyomavirus by Ludwik Gross in 1953. Gross
demonstrated that a transmissible agent, the now-archetypal
murine polyomavirus (MPyV), induced tumors in mice (Gross,DAPI
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understated, and include discoveries of p53 (Lane and Crawford,
1979; Linzer and Levine, 1979), the ﬁrst nuclear localization signal
(Lanford and Butel, 1984), tyrosine phosphorylation (Eckhart et al.,
1979) and PI3K signaling (Whitman et al., 1985), and basic
mechanisms in the process of DNA replication (Li and Kelly, 1984;
Waga and Stillman, 1994).
The detection of polyomaviruses that infect humans has rapidly
escalated in the last decade. There are currently eleven identiﬁed
human polyomaviruses, nine of which have been discovered in
the last ﬁve years (Reviewed in Buck et al., 2012; Chang and
Moore, 2012; Siebrasse et al., 2012). Nearly half of these human
polyomaviruses are linked to human diseases, although many of
these associations remain tenuous. To date, Merkel Cell Polyoma-
virus (MCPyV; also referred to as MCV) is the only human
polyomavirus with a robust collection of scientiﬁc evidence sup-
porting its classiﬁcation as a causative agent of a human malig-
nancy, Merkel Cell Carcinoma (MCC).Merkel cells and Merkel cell carcinoma
First described as ‘touch cells’ by Friedrich Sigmund Merkel in
1875, Merkel cells are found in hair follicles, certain mucosal
tissues, and are most abundant in areas of the skin involved in
the sensation of touch (Fig. 1A). In vertebrate skin, Merkel cells are
located in the basal layer of the epidermis, and it is here where the
structure and function of these cells are best characterized. At their
position adjacent to the dermis, Merkel cells are bound to the
terminal ends of sensory nerve ﬁbers. These nerve-associated
Merkel cells serve as mechanoreceptors that transduce mechanical
stimuli from the skin. Morphological and ultrastructural character-
istics of Merkel cells include a round or oval shape, electron-dense
core secretory granules surrounded by a clear ‘halo’, and spinous
projections on their surface. A panel of immunohistochemical
markers is used to detect and distinguish Merkel cells, and
typically includes cytokeratins 8, 18, 19, and 20 and the neuroen-
docrine markers chromogranin A, synaptophisin, and neuron-
speciﬁc enolase (Fig. 1B). Of these markers, cytokeratin 20 is
considered the most sensitive and speciﬁc diagnostic marker of
Merkel cells. (Reviewed in Gould et al., 1985; Halata et al., 2003;
Lucarz and Brand, 2007; Moll et al., 2005; Sidhu et al., 2005).
Merkel cell carcinoma (MCC) is a malignancy of cutaneous
neuroendocrine cells, and is therefore generally believed to origi-
nate from the transformation of Merkel cells (Gould et al., 1985). It
was ﬁrst described by Toker in 1972 (Toker, 1972), yet the
pathogenesis and etiology of MCC remains complex and poorly
understood. Approximately 1500 new cases of MCC are diagnosed
per year in the US, representing a relatively rare cancer; however,
the incidence of MCC has tripled in the last two decades and
annual diagnoses continue to climb by 5–10% (Agelli and Clegg,
2003; Becker et al., 2009b; Calder and Smoller, 2010; Hodgson,
2005; Lemos and Nghiem, 2007). Moreover, despite the rarity of
MCC, it is one of the most lethal and aggressive skin cancers with a
mortality rate greater than 30% (Hodgson, 2005).
The most common clinical features of MCC are summarized by
the acronym ‘‘AEIOU’’ (Heath et al., 2008): Asymptomatic, Expand-
ing rapidly, Immune suppression, Older than age 50, and UV-
exposed site on a fair-skinned individual. There is a striking
increase in the incidence of MCC in HIV-infected individuals
(Engels et al., 2002), chronic lymphocytic leukemia patients (Vlad
and Woodlock, 2003), and following organ transplantation (Buell
et al., 2002; Heath et al., 2008; Penn and First, 1999). MCC is
primarily a disease of the elderly, with the mean age of onset for
men and women being 74 and 76 years of age, respectively (Agelli
and Clegg, 2003). In addition, MCC occurs almost exclusively inCaucasians at sites of the body that are frequently sun-exposed,
and disease rates are correlated with equatorial proximity (Agelli
and Clegg, 2003; Albores-Saavedra et al., 2010; Heath et al., 2008;
Miller and Rabkin, 1999). Interestingly, Merkel cells are more
concentrated in sun-exposed compared to non-exposed skin
(Moll et al., 1990) and UV-speciﬁc mutations have been observed
in the p53 gene of MCCs (Popp et al., 2002). Taken together, these
statistics suggest that a combination of immunosuppression and
the potential oncogenic pathways elicited by UV exposure are
involved in MCC pathogenesis, yet these factors alone do not fully
account for the etiology of MCC.Discovery of Merkel cell polyomavirus
Based mainly on the aforementioned link between MCC and
immune suppression, the research team led by Patrick Moore and
Yuan Chang at the University of Pittsburgh sought to determine
whether MCC has an infectious origin. This group, in particular, was
well-suited for the search given their previous discovery of Kaposi’s
sarcoma-associated herpesvirus (KSHV) in AIDS-associated Kaposi’s
sarcoma tissue using a technique known as representational
difference analysis (RDA) (Chang et al., 1994). RDA uses PCR
ampliﬁcation of restriction fragments to create ‘representations’ of
the DNA genome of normal or diseased tissue. After ligating the
diseased tissue representation with priming sequences, it is mixed
with unligated representation DNA from normal tissue. Following
multiple rounds of PCR ampliﬁcation in a subtractive hybridization
process, those sequences that fail to hybridize with normal tissue
counterparts become doubly primed and thus enriched during PCR.
While the RDA technique was used to successfully identify KSHV, it
relies heavily on the presence of non-diseased tissue controls and is
rather non-quantitative.
To begin the search for viral sequences in MCC, the Chang–
Moore research group built on the principles of RDA and moder-
nized the technique by combining it with the availability of
sequences from the entire human genome. The product was a
related but distinct method known as digital transcriptome sub-
straction (DTS) (Feng et al., 2007). DTS uses a combination of high-
throughput cDNA sequencing and in silico methods to sequentially
exclude human sequences from a tissue sample transcriptome. For
each normal or diseased sample, cDNA libraries are created and
then subjected to sequencing, and the results compared to human
sequence databases. In 2008, the DTS technique was applied to
four MCC tumors and revealed previously unidentiﬁed viral tran-
scripts with high sequence-identity to archival polyomavirus
tumor antigen (T antigen) sequences. Ultimately, a full-length,
5.4 kilobase circular viral genome (prototype MCV350) was
sequenced from a MCC tumor and was aptly named Merkel cell
polyomavirus (Feng et al., 2008).
The Merkel cell polyomavirus (MCPyV) genome is similar to
other human polyomaviruses in that it includes a conserved
replication origin, as well as opposing early and late gene regions
that express small and large T antigens (sT and LT) and VP1, VP2,
and VP3, respectively (Feng et al., 2008; Shuda et al., 2008). While
many domains of MCPyV share homology with their well-studied
human polyomavirus counterparts, the MCPyV genome is most
similar to the African Green Monkey lymphotropic polyomavirus
and is phylogenetically classiﬁed in the murine polyomavirus
clade (Dalianis et al., 2009; Feng et al., 2008). However, based on
the most recent and revised taxonomical classiﬁcation of the
Polyomaviridae family, MCPyV is now classiﬁed in the Orthopo-
lyomavirus genus designated for mammalian virus species sharing
high nucleotide sequence similarity (Johne et al., 2011).
Fig. 2. The Merkel Cell Polyomavirus (MCPyV) genome and capsids. (A) Schematic
of the MCPyV prototype MCV350. The double-stranded DNA genome is approxi-
mately 5.4 kilobases in length. The bi-directional origin of replication (white)
promotes temporal expression of discrete regions of the genome. The early region
encodes three viral T antigens: large T antigen (LT; red), 57 kT antigen (57 kT;
orange) and small t antigen (sT; yellow). The late region is transcribed in the
opposite direction from the origin and encodes the viral structural proteins: the
major capsid protein Virus Protein 1 (VP1; green), and the minor capsid proteins
Virus Protein 2 and Virus Protein 3 (VP2; blue, VP3; gray). (B) Transmission
electron micrograph of MCPyV virus-like particles composed of VP1 and VP2
proteins. The VP1 and VP2 proteins self-assemble into 50 nm icosahedral
particles. (Scale bar¼100 nm).
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As mentioned above, the genetic components and organization of
the MCPyV genome are largely similar to other polyomaviruses
(Reviewed in Chang and Moore, 2012; Feng et al., 2008). The
prototype virus MCV350 has a circular, double-stranded DNA
genome of 5387 base-pairs, and the genomes of all subsequent
MCPyV strains sequenced to date average 5.4 kilobases (Fig. 2). As
is customary for polyomaviruses, the MCPyV genome contains
bidirectional early and late coding regions, separated by a
non-coding regulatory region that houses the viral replication origin.
The segregation of the early and late transcriptional units promotes
a temporally regulated cascade of gene expression distinguished by
the onset of viral DNA replication, a replication scheme consistent
with other DNA viruses (Feng et al., 2011). The early genes, namely
the products of the T antigen locus, are expressed immediately upon
infection and are generally involved in replication of the viral DNA
genome. Following DNA replication, the late region is transcription-
ally activated to express gene products that are structural compo-
nents of the viral capsid and contribute to progeny virion production
during the late phase of infection (Cole and Conzen, 2001). Despite
these similarities, the MCPyV viral genome has several uniquegenetic characteristics compared to other human polyomaviruses.
As one example, gene products of both the early (large and small T
antigens) and late regions (VP1 and VP2) of Merkel cell polyoma-
virus are more closely related to murine polyomaviruses than to the
other human polyomaviruses (Feng et al., 2008).
Origin of replication
The non-coding regulatory region (NCRR) of MCPyV contains a
71-base pair minimum origin of replication that, like other
polyomaviruses, has an AT-rich tract, LT-binding domain, and
early enhancer region. However, the MCPyV origin of replication
has several unique characteristics. Polyomavirus origins of repli-
cation traditionally contain pentanucleotide consensus sequences
G(A/G)GGC that help direct assembly of LT proteins on the DNA
by speciﬁcally binding the origin-binding domain (OBD) within
the central portion of LT, an event that in turn allows LT to
function as a helicase and direct the initiation of viral DNA
replication (Reviewed in Cole and Conzen, 2001; Fanning and
Zhao, 2009; Pipas, 1992). In the MCPyV origin, however, there are
more pentanucleotide sequences than any other polyomavirus,
and these pentameric elements exist in closer proximity to one
another than in other polyomaviral origins (Johnson, 2010; Kwun
et al., 2009). Kwun and colleagues suggested that this close
proximity likely allows OBD–OBD interaction between LT pro-
teins bound at the origin. More recently, a crystal structure of the
MCPyV LT OBD in complex with a segment of the MCPyV origin of
replication was reported and veriﬁes that OBD–OBD intermole-
cular interactions occur on LT proteins bound to the origin of
replication (Harrison et al., 2011). As determined by mutational
analysis, these OBD–OBD interactions are not required for LT
binding to the origin, nor do they appear to affect the structure of
the viral DNA. Such intermolecular interactions do not occur on
the SV40 origin, as the OBD-binding pentanucleotide sequences
are more spatially separated (Bochkareva et al., 2006; Meinke
et al., 2007). Secondary-structure matching analysis reveals a
striking similarity between MCPyV LT and the E1 origin-binding
protein of bovine papillomavirus (Harrison et al., 2011). The
crystal structure also conﬁrmed the previous report by Kwun et
al. of the unique combination of pentanucleotide sequences that
are required for efﬁcient MCPyV replication. Taken together, these
features indicate that replication at the MCPyV viral origin and
the process of LT seeding may be somewhat distinct and more
complex in comparison to other polyomaviruses.
Early region: The T antigen locus
The MCPyV early region spans nearly 3 kilobases of the 5.4 kilo-
base genome, and its genes are the ﬁrst to be expressed upon
infection (Feng et al., 2008, 2011; Neumann et al., 2011). Poly-
omavirus early region gene products historically target cellular
proteins that function in cell cycle regulation and tumor suppres-
sion (DeCaprio et al., 1988; Lane and Crawford, 1979; Linzer and
Levine, 1979; Pallas et al., 1990). Because these gene products are
designated as tumor antigens, or T antigens, the early region is
frequently referred to as the ‘‘T antigen locus’’. The polyomavirus T
antigens also perform key functions in the initiation of viral DNA
synthesis. The MCPyV early region expresses three T antigens:
large T antigen (LT), small T antigen (sT), and 57kT antigen (57 kT)
(Feng et al., 2008; Shuda et al., 2008, 2009). There is no evidence
that MCPyV expresses proteins analogous to middle T antigen or
agnoprotein expressed by other polyomaviruses. The basic genetic
features and functional domains of the three MCPyV T antigens
will be reviewed in the following section. Discussion of their roles
in viral replication and their potential roles in transformation and
57 kT
Location of MCC Tumor-Specific MutationsMUR
1 1000 2000 3000
sT
PP2A
Binding
Genomic DNA
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CR1 OBD HelicaseNLS
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BindingDnaJ
MCV-mIR-M1-5p
Fig. 3. The MCPyV T antigen locus. The MCPyV T antigen locus is located in the early region of the genome and encodes three T antigen isoforms that arise by alternative
splicing. The large T antigen (LT) shares many traditional domains found in other polyomaviruses: CR1 (LXXLL; black), DnaJ (HPDKGG; pink), pRb-binding (LXCXE; red), a
nuclear localization signal (NLS; orange), origin-binding domain (OBD; purple), and a helicase domain (green). LT also contains unique features, such as a binding site for
Vam6p (blue) and a 200-amino acid ‘‘MCV-Unique Region’’ (MUR). The location of reported tumor-speciﬁc mutations in the 30 region of LT is depicted with a red bar. The
site of MCPyV microRNA (MCV-mIR-M1-5p) complementarity in LT is denoted (black arrow). The small t antigen (sT) shares the ﬁrst exon with LT, but due to alternative
splicing also contains a protein phosphatase 2A-binding site (PP2A; yellow). The 57 kT antigen is identical to LT up to the NLS motif, at which point differential splicing
precludes the inclusion of complete OBD and helicase domains.
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sections.
All three MCPyV T antigens share a short, common amino-
terminus, but alternative splicing downstream of the ﬁrst exon
ultimately gives rise to three unique proteins (Fig. 3). The MCPyV
LT protein is the largest of the three T antigens and is composed of
two exons that together encode for a protein of 816 amino acids.
As shown in Fig. 3, MCPyV LT has conserved features important
for well-characterized LT functions, including CR1 (LXXLL) and
DnaJ (HPDKGG) domains, a pRb-binding domain (LXCXE), an
origin-binding domain (OBD), and a helicase domain (Reviewed
in Pipas, 1992). For this reason, it is inferred that MCPyV LT
generally shares many functions with other polyomavirus LTs.
A nuclear localization signal (NLS) is located between the
pRb-binding LXCXE motif and the OBD and is conserved in other
MCPyV isolates (Nakamura et al., 2010). The carboxyl terminal
half of LT contains most of the domains involved in viral DNA
replication, including the OBD, ATPase domain, and helicase
domains. This region of LT is also the site of tumor-speciﬁc
mutations, the signiﬁcance of which will be discussed in further
detail in later sections. It should be noted that MCPyV LT is clearly
distinct from other human polyomaviruses and shares only 30%
amino acid identity with their human polyomavirus counterparts
(Feng et al., 2008; Johnson, 2010). One unique aspect of MCPyV LT
is the presence of approximately 200 additional amino acids at
the beginning of exon 2 just proximal to the pRb-binding LXCXE
domain called the ‘‘MCV-Unique Region’’, or MUR. The MUR
region of LT binds a cellular factor, Vam6p, and redistributes it
to the nucleus. This function appears to be unique to MCPyV LT(Liu et al., 2011). The MCPyV LT pRb-binding domain is unique in
that it contains a ‘spacer region’ that effectively separates the
‘Psycho’ domain from the LXCXE motif, and also contains com-
plementary sequence for a MCPyV viral microRNA (Johnson,
2010; Seo et al., 2009). This region is unique to MCPyV LT and
is contained within the MUR described by Liu and colleagues, but
the effects of this additional sequence on LT function have not yet
been determined.
In addition to LT, the T antigen locus of MCPyV encodes for a
small T (sT) protein. As mentioned previously, the MCPyV sT
protein shares the same amino terminus with LT and 57 kT
(Fig. 3) and therefore has conserved region 1 (CR1) and heat
shock protein-binding (DnaJ) motifs. However, transcriptional
read-through of the ﬁrst exon splice site used by LT and 57 kT
gives rise to a small protein of 186 amino acids with a unique
carboxyl terminus that harbors a protein phosphatase 2A (PP2A)
binding site. The ability to bind PP2A is a conserved function of
polyomavirus sT proteins and this association has been shown to
play an important role in virus-induced cellular transformation by
other polyomaviruses (Pallas et al., 1990). A recent study by Shuda
and colleagues provided initial insight into the functional char-
acteristics of MCPyV sT protein, which include physical association
between sT and the PP2A Aa subunit in co-immunoprecipitation
assays and promoting sustained phosphorylation of the cellular
translation factor eIF4E binding protein 1 (4E-BP1) (Shuda et al.,
2011). So far, the MCPyV sT protein has been implicated in the
process of viral DNA replication (Feng et al., 2011; Kwun et al.,
2009) and cellular transformation (Shuda et al., 2011), both func-
tions that will be explored in further detail in upcoming sections.
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The 57 kT protein is the product of a transcript that undergoes
alternative splicing to join three exons encoding for 432 amino
acids, and this protein shares many of the same motifs present in LT
and sT. The 57 kT protein has the same amino terminus as both LT
and sT, including the CR1 and DnaJ domains, and also contains the
MUR, pRb-binding LXCXE motif, and the most C-terminal 100 amino
acids that are present in LT. Information on the role of 57 kT in the
viral life cycle or MCPyV-induced tumorigenesis is sparse. The 57 kT
antigen is frequently described as an analog of the SV40 17 kT
antigen (Zerrahn et al., 1993), which appears to function both
independently of and in cooperation with the other T antigens in
the process of cellular proliferation in vivo (Comerford et al., 2012).
The late region: Structural proteins
The late region of the MCPyV genome contains open reading
frames for the major capsid protein viral protein 1 (VP1) and the
minor capsid proteins 2 and 3 (VP2 and VP3). Interestingly,
MCPyV lacks the conserved genetic architecture that normally
gives rise to the VP3 protein. This sequence aberration, coupled
with failed attempts to create viable VP3 expression vectors
(Pastrana et al., 2009) and abnormal VP1 localization reminiscent
of polyomaviruses lacking a VP3 protein (Neumann et al., 2011),
suggests that MCPyV either expresses a non-functional VP3 or
does not express this protein at all. Regardless, MCPyV particles
composed of VP1 and VP2, either as a result of their ectopic
expression and self-assembly into virus-like particles (VLPs)
(Tolstov et al., 2009) or from replication of genetically engineered
consensus genomes (Feng et al., 2011; Neumann et al., 2011;
Schowalter et al., 2011), have an average particle size (40–
55 nm) consistent with other polyomavirus particles (Fig. 2B).
MCPyV microRNA
The MCPyV genome expresses a 22-nucleotide viral miRNA
(MCV-miR-M1-5p) from the late strand that most likely auto-
regulates early viral gene expression during the late phase of
infection, as it was shown to reduce the level of reporter
transcripts containing MCPyV early region sequences (Lee et al.,
2011; Seo et al., 2009). This miRNA has complete reverse
complementarity to a sequence in LT adjacent to the LXCXE
motif, implying that it targets this early protein for autoregula-
tion, and is also predicted to affect a variety of cellular targets
with potentially relevant functions in transformation (Johnson,
2010; Lee et al., 2011; Seo et al., 2009). One study reported that
miRNA expression is preserved in approximately 50% of MCPyV-
positive MCC tumors, and the level of miRNA expression corre-
lates with viral genome copy number in the tumor (Lee et al.,
2011). The presence of MCPyV miRNA in MCC tumors certainly
warrants further investigation into its role, if any, in the patho-
genesis of MCC.
Overall, while the MCPyV genome sequence and organization
is reminiscent of other members of the Polyomaviridae family,
there are clearly some unique characteristics that may suggest
this new human polyomavirus has evolved to have divergent
mechanisms and functions for reasons not yet fully appreciated.MCPyV molecular virology: Virus life cycle and replication
MCPyV was originally discovered in MCC, and it is within this
malignant milieu where most of its molecular virology is cur-
rently being characterized. Details regarding the naturally occur-
ring life cycle and replication of MCPyV are limited as there
is no cell culture system yet identiﬁed in which virus can bepropagated, except for one in which viral LT and sT genes are
expressed in trans. Moreover, the precise cellular tropism and cell
type that supports productive MCPyV infection remain unclear.
These limitations have resulted in a reliance on cell culture-based
systems, combined with genetically engineered consensus gen-
omes or pseudoviruses, for the study of the MCPyV life cycle and
replication.
Attachment and entry
A report by Erickson et al. ﬁrst identiﬁed a potential cellular
receptor for MCPyV (Erickson et al., 2009). Through the use of
hemagluttination and sucrose gradient ﬂotation assays, the authors
found that MCPyV capsomeres composed of recombinant VP1
proteins bound sialic acid components of the ganglioside Gt1b.
The results of this initial study suggested that MCPyV abides by the
typical attachment and uptake processes used by other polyoma-
viruses, which primarily utilize carbohydrates with sialic acid as
primary receptors (Reviewed in Neu et al., 2009). However,
subsequent studies suggest a more nuanced scenario. Schowalter,
Pastrana, and Buck tested the ability of MCPyV pseudovirions
(composed of VP1, VP2, and a luciferase reporter plasmid) to bind
and transduce encapsidated reporter DNA to the nucleus of
cultured A549 cells (Schowalter et al., 2011). They presented
compelling evidence that MCPyV requires sulfated glycosamino-
glycans, particularly heparan sulfate, for infectious entry. This is
not unlike what is thought to be the case for papillomaviruses
(Reviewed in Horvath et al., 2010). Interestingly, while MCPyV
pseudovirions efﬁciently bound to Lec2 cells that lack sialylated
glycans like Gt1b, the particles were deﬁcient in gene transduction.
These results led the authors to speculate that MCPyV utilizes a
glycosaminoglycan as a primary receptor, but then requires a
sialylated glycan as a post-attachment co-receptor for gene trans-
duction. Determination of the MCPyV VP1 crystal structure ulti-
mately supports this model (Neu et al., 2012). Neu and colleagues
identiﬁed sialic acid binding sites on VP1 that are required for a
post-attachment step in MCPyV infectious entry; however, muta-
tion of these sites did not preclude initial cellular attachment of
MCPyV pseudovirions. Taken together, these initial reports suggest
a novel infectious entry process that requires glycosaminoglycans
for initial attachment and subsequent association with sialic acid
for gene transduction. The use of sialic acid as a secondary receptor
by MCPyV differs from the current consensus for other polyoma-
viruses (Neu et al., 2011), and provides further evidence that this
virus is unique among Polyomaviridae family members.
In vitro replication studies
Other recent efforts have focused on characterization of MCPyV
tissue tropism and replication. The ability of a cell type or tissue to
support efﬁcient infectious entry of a virus particle and ultimately
support the production of infectious progeny virions can imply
tropism of a virus. So far, no clear tropism has been deﬁned for
MCPyV. In one report, the infectivity of MCPyV pseudovirions was
determined on a panel of sixty human cancer cell lines (NCI-60) by
measuring infectious entry of an encapsidated reporter gene
(Schowalter et al., 2012). While MCPyV transduced a wide spec-
trum of cell types and no clear tropism emerged, human skin-
derived primary keratinocytes (HEKa) and transformedmelanocyte
(melanoma) cell lines supported infectious entry of MCPyV pseu-
dovirions. On the other hand, a transformed keratinocyte cell line
(HaCat) and primary melanocytes were resistant to MCPyV pseu-
dovirus entry. These results suggest the need for cautious inter-
pretation of research using cultured cell lines to study MCPyV
tropism, but may also imply that the skin is a preferential site for
MCPyV infection.
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omes to study the MCPyV life cycle and the roles of cellular and
host proteins in virus replication. Multiple reports were published
around the same time attempting to recapitulate the virus life
cycle in cultured cells (Feng et al., 2011; Neumann et al., 2011;
Schowalter et al., 2011). In the reports by Feng and Neumann,
consensus MCPyV genomes were synthesized that each share high
homology to DNA found within encapsidated virions shed from
healthy human skin (Schowalter et al., 2010). In the report by Feng
et al., weak viral DNA replication and expression of all three T
antigen species (LT, sT, 57 kT) and VP1 were detected by Southern
blot and immunoblot, respectively, 2–5 days following transfection
of circularized MCV-HF DNA genome into 293 cells. Likewise,
Neumann et al. observed replicated genomic DNA and expression
of both LT and VP1 transcripts and protein following transfection of
circularized MCV-Syn DNA genome. Acknowledging widely variable
transfection efﬁciencies between cell lines, only 3 out of 22 lines
tested supported early and late gene expression: human embryonic
kidney cells (293), human non-small cell lung carcinoma cells
(H1299), and a human neuroectodermal cell line (PFSK-1)
(Neumann et al., 2011). Both groups observed gene expression
kinetics consistent with a systematic early to late cascade of gene
expression that culminated in the detection of virus particles by
approximately 4 days post-transfection, although Neumann et al.
observed smaller and more irregularly shaped MCPyV particles than
the SV40 counterparts synthesized in a parallel control experiment.
In the study by Schowalter et al., 2011, MCPyV virions produced in
293TT cells cotransfected with a viral genome isolated from healthy
skin and VP1/2 expression vectors were used to infect a cell line
expressing the MCPyV LT and sT genes in trans (293-4T). Over a
several week period, modest replication of the input viral DNA
genome and synthesis of VP1 protein was observed, as well as
production of new virus particles (as judged by quantifying yield of
virions from cell culture following lysis of the cells). This experi-
mental system, while artiﬁcal in that LT and sT are being expressed
in trans, comes the closest, to date, to providing the means to study
the full life cycle of MCPyV in a laboratory setting, and an efﬁcient
means for producing the virus.
Viral and cellular factors involved in replication
The cellular and viral genes required for efﬁcient MCPyV
replication are also coming into focus. Based on other polyoma-
virus replication schemes, the MCPyV T antigens would be
expected to play critical roles in the virus life cycle. Results of
in vitro studies on the MCPyV origin of replication conﬁrm these
predictions, revealing that LT activity is required for efﬁcient DNA
replication and is greatly enhanced by sT (Kwun et al., 2009). The
57 kT antigen does not appear to play a role in replication, and its
function in the viral life cycle remains unknown. Mutational
analysis of sT indicates that association with PP2A is required
for its ability to enhance LT’s viral DNA replication function.
Interestingly, the shared DnaJ motif in the amino terminal portion
of LT/sT (Fig. 3) is required for LT function in replication, but is
dispensable in the context of sT’s ability to augment LT’s DNA
replication functions. The role of LT and sT in viral DNA replica-
tion is supported by in vitro replication studies. Replication of
consensus genomes is greatly enhanced by co-expressing sT, and
to a lesser extent LT (Feng et al., 2011), or by supplying the early
region in trans (Neumann et al., 2011). And as described above,
293-4T cells, which constitutively express both MCPyV LT and sT
proteins, could support not only replication but also produce
virions when infected with MCPyV virus (Schowalter et al., 2011).
So far, Vam6p is the only cellular factor shown to affect MCPyV
replication, which greatly antagonizes MCPyV replication through
its interaction with LT (Feng et al., 2011).Transmission studies
Despite the advances made in understanding MCPyV replica-
tion through in vitro replication assays, all experiments have so
far failed to detect cytopathic effect (CPE) or robust serial
transmission of virions produced in these culture systems. Co-
culture of 293 cells transfected with the MCV-HF DNA genome, in
which early and late genes are expressed and virus particles were
detected, with naı¨ve cell populations failed to promote secondary
virus infection or CPE (Feng et al., 2011). Moreover, repeated
freeze/thaw cycles to release cell-associated virions also failed to
promote horizontal spread of MCPyV virus (Neumann et al.,
2011). These ﬁndings indicate that a bona ﬁde experimental
system for MCPyV virus propagation in the laboratory has not
yet been fully developed. It has now been established that MCPyV
DNA (Feng et al., 2008; Foulongne et al., 2010a, 2010b; Loyo et al.,
2010; Wieland et al., 2009) and encapsidated virions (Schowalter
et al., 2010) can be detected on normal human skin. The location
of MCPyV detection supports the notion that MCPyV is part
of the normal microﬂora of human skin. In fact, the primary
events of MCPyV replication have been shown to occur in
cultured monolayers of primary keratinocytes, which are a
prominent cell type of the skin and other stratiﬁed epithelia
(Schowalter et al., 2011). Taken together with the difﬁculty in
reproducing the MCPyV virus life cycle in monolayer cell culture,
especially the production of infectious progeny virions and sub-
sequent virus transmission, these ﬁndings may imply a depen-
dence on the process of differentiation in the stratiﬁed epithelium
of the skin. Through this consideration, the potential to formulate a
better model of MCPyV tissue tropism and virus propagation can be
developed. The understanding of the context of a natural MCPyV
infection, including its life cycle, host range, and the isolation of
intact virus, remains limited but these discoveries will certainly
provide insight into the relation of MCPyV to other polyomaviruses.MCPyV epidemiology
Since its discovery in 2008, epidemiological studies have
established MCPyV as a common virus infecting the human
population. Enzyme immunoassays speciﬁc for the immunogenic
determinant of MCPyV, the major capsid protein VP1, have been
used to determine that up to 80% of the adult population contains
serum antibodies to MCPyV (Carter et al., 2009; Kean et al., 2009;
Pastrana et al., 2009; Tolstov et al., 2011; Tolstov et al., 2009; Touze
et al., 2010). Seropositivity to MCPyV is essentially nonexistent in
prenatal blood spots (Gustafsson et al., 2012), yet becomes widely
prevalent in children in their ﬁrst decade of life and continues to
increase with age, suggesting exposure to the virus occurs during
early childhood (Chen et al., 2011; Kean et al., 2009; Tolstov et al.,
2009; Viscidi et al., 2011). By monitoring overt symptoms along-
side seroconversion of MCPyV-seronegative individuals, it appears
that MCPyV infection is mostly asymptomatic (Tolstov et al., 2011).
Viral DNA has been detected in a wide variety of anatomical
locations, including the respiratory tract (Babakir-Mina et al.,
2010; Bialasiewicz et al., 2009; Goh et al., 2009; Kantola et al.,
2009), saliva (Foulongne et al., 2010b; Loyo et al., 2010), lymphoid
tissues (Sharp et al., 2009; Shuda et al., 2009; Toracchio et al.,
2010), urine (Boﬁll-Mas et al., 2010; Husseiny et al., 2010; Laude
et al., 2010; Mertz et al., 2010), and the gastrointestinal tract
(Campello et al., 2011; Feng et al., 2008). Viral DNA detection in
these locations is relatively low compared to the skin, where both
viral DNA and encapsidated virions can be detected (Feng et al.,
2008; Foulongne et al., 2010a, 2010b; Loyo et al., 2010; Schowalter
et al., 2010; Wieland et al., 2009). No route of transmission for
MCPyV has been validated, but available data supports several
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gastrointestinal tract, and urban sewage suggests a fecal-oral mode
of transmission (Boﬁll-Mas et al., 2010; Campello et al., 2011; Loyo
et al., 2010), while presence in the aerodigestive tract supports a
respiratory route (Babakir-Mina et al., 2010; Kantola et al., 2009;
Tolstov et al., 2009). The discovery that nuclease-resistant MCPyV
DNA (presumably encapsidated virus) is chronically shed from the
skin (Schowalter et al., 2010) and is present on a variety of
environmental surfaces (Foulongne et al., 2011), along with the
emerging hypothesis that the MCPyV life cycle may be linked to
cellular differentiation, could imply a mode of transmission that
stems from cutaneous shedding of MCPyV virus.MCPyV and MCC: Association and evidence for causality
Merkel cell polyomavirus was originally isolated from MCC
tissue samples. In the hallmark report announcing their discovery
of MCPyV, Feng and colleagues established the initial framework
for a causal relationship between the virus and MCC (Feng et al.,
2008). There are now several lines of evidence that suggest
MCPyV is an etiological agent of MCC. One of the most unequi-
vocal ﬁndings is the presence of the viral genome in a majority of
MCCs. Using PCR to detect MCPyV-speciﬁc sequences, Feng et al.
reported the presence of MCPyV in 8 out of 10 (80%) MCC tumors
tested. Since this original report, there has been widespread
conﬁrmation of these results that together indicate around 75%
of MCCs contain MCPyV DNA (Andres et al., 2009; Becker et al.,
2009a; Busam et al., 2009; Carter et al., 2009; Duncavage et al.,
2009; Fischer et al., 2010; Garneski et al., 2009; Kassem et al.,
2008; Katano et al., 2009; Loyo et al., 2010; Sastre-Garau et al.,
2009; Varga et al., 2009). In the 8 MCPyV-positive MCCs originally
analyzed, the viral genome copy number was subsequently found
to average at least 1 copy per tumor cell (Shuda et al., 2009),
although a vast range of viral copy numbers have since been
reported (Bhatia et al., 2010b; Houben et al., 2010a; Katano et al.,
2009; Laude et al., 2010). Along these lines, MCC patients were
found to have much higher MCPyV antibody titers than the
general public, even if the tumor tested negative for the virus,
indicating a strong association between MCPyV and MCC and a
possible viral role in tumor initiation (Carter et al., 2009; Pastrana
et al., 2009; Tolstov et al., 2009; Viscidi et al., 2011).
Perhaps one of the more persuasive pieces of evidence sup-
porting the theory that MCPyV is an etiological factor of MCC is
clonal integration of the viral genome into the cellular genomes of
MCC tumors (Feng et al., 2008; Laude et al., 2010; Martel-Jantin
et al., 2012; Sastre-Garau et al., 2009) and some MCC cell lines
(Fischer et al., 2010). MCC tumor metastases are also MCPyV-
positive and share the same integration pattern as the original
tumor (Feng et al., 2008; Laude et al., 2010). Collectively, these
ﬁndings strongly suggest MCPyV virus infection occurs in a cell
that ultimately gives rise to neoplastic growth and clonal expan-
sion. The virus appears to integrate as head-to-tail concatemers at
distinct locations randomly distributed throughout the cellular
genome, and any evidence for cellular ‘hot-spots’ of viral integration
does not currently exist (Feng et al., 2008; Laude et al., 2010; Martel-
Jantin et al., 2012; Sastre-Garau et al., 2009). The precise mechan-
isms that direct integration of the MCPyV genome and the contribu-
tion of exogenous inﬂuences in this process are not yet understood.
Another line of evidence supporting causality is the retention
of MCPyV gene expression in MCCs. Transcripts for MCPyV T
antigens are consistently detected in MCC tumors (Feng et al.,
2008; Sastre-Garau et al., 2009; Shuda et al., 2008). Moreover,
MCPyV T antigen protein expression has been observed in MCC
tumor sections by immunohistochemistry (Bhatia et al., 2010a;
Busam et al., 2009; Shuda et al., 2009, 2011). Most, but not all,MCC tumors are positive for MCPyV LT, and only cells within the
tumor are reactive to LT antibodies while neighboring tissue is
negative (Shuda et al., 2009). Interestingly, many tumors negative
for LT exhibit positive staining with an antibody speciﬁc to sT, and
additional analysis suggests that sT is actually more frequently
expressed in MCC tumors than LT (Shuda et al., 2011). The
signiﬁcance of T antigen expression to MCPyV-induced carcino-
genesis is strongly reinforced by the ﬁnding that their expression
is required for growth of MCPyV-infected MCC cell lines. In a
study by Houben et. al., shRNAs targeting the ﬁrst exon shared by
all T antigens were used to knockdown T antigen expression in
MCC cell lines, resulting in impeded cell proliferation and survival
(Houben et al., 2010b). The individual requirements for LT and sT
in MCPyV-positive MCC cell growth were further dissected using
shRNA speciﬁcally targeting sT antigen. Whereas sT knockdown
inhibited cell growth to a level comparable to knockdown of all T
antigens, it did not promote the robust cell cycle arrest or cell
death seen in cells with pan-T antigen knockdown (Shuda et al.,
2011). These data suggest that LT and sT most likely contribute to
MCPyV-induced carcinogenesis via distinct mechanisms, but are
both required for optimal MCC tumor cell growth.
A common characteristic of viral oncogenesis is a combination
of events that renders the virus incapable of replication, yet still
proﬁcient in the induction of cellular proliferation (Reviewed in
Moore and Chang, 2010). Clearly, integration of the MCPyV
genome creates a barrier to virus replication, as explained below,
but there are also features of tumor-associated MCPyV genomes
that further suggest a strong selective pressure within MCCs to
abrogate virus replication while preserving proliferative func-
tions. Several groups have reported mutations in the origin of
replication and VP1 gene in MCC-derived MCPyV genomic
sequences that prevent efﬁcient replication and progeny virion
production, respectively (Feng et al., 2011; Kassem et al., 2008;
Kwun et al., 2009; Neumann et al., 2011). However, the most
common tumor-speciﬁc MCPyV mutations occur in the LT anti-
gen. The LT antigen sequences in almost all tumor-derived MCPyV
isolates and MCC cell lines analyzed to date contain mutations
within exon 2 that prematurely truncate the LT protein (Fischer
et al., 2010; Katano et al., 2009; Laude et al., 2010; Shuda et al.,
2008) (Fig. 3). Strikingly, these mutations all occur within the
carboxy terminus of LT at sites downstream of the LXCXE Rb-
binding motif. This consistent, tumor-speciﬁc mutational pattern
gives rise to truncated LT antigens in which the CR1, DnaJ, MUR,
NLS, and pRb-binding motifs are preserved, yet domains asso-
ciated with replication are lost. Indeed, truncated LT proteins can
still co-immunoprecipitate pRb but are defective for origin-
binding and viral helicase activities, and are thus no longer
functional in replication assays (Shuda et al., 2008). These muta-
tions in LT lie within a region that does not affect the coding
capacity for sT. The presence of tumor-speciﬁc mutations within
the MCPyV genome is compelling evidence that the virus has lost
the capacity to replicate in MCC tumors, but retains motifs with
potential to contribute to uncontrolled proliferation.
Given the preponderance of evidence associating MCPyV with
MCC, the knowledge that MCPyV genes are required for the growth
of MCC-derived cell lines, and the transforming potential of MCPyV
genes, it is not surprising that the World Health Organization’s
International Agency for Research on Cancer has recently classiﬁed
MCPyV as a group 2A carcinogen, a designation meaning it is
‘‘probably carcinogenic to humans’’ (Bouvard et al., 2012).Potential mechanisms of MCPyV transformation
Considering the status of the MCPyV genome and T antigens
found in MCC tissue, several mechanisms of virus-induced
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the constitutive expression of LT and sT proteins. Using SV40 as a
reference (Reviewed in Ahuja et al., 2005; Khalili et al., 2008;
Hahn et al., 2002), one might hypothesize that MCPyV LT is the
main viral oncoprotein and sT plays an accessory role in trans-
formation by MCPyV. However, emerging data is starting to
support the already accumulating evidence that MCPyV is unique
with respect to other polyomaviruses. Multiple groups have
observed that pan-T antigen knockdown in MCC cell lines con-
tributes to robust cell death and cell cycle arrest (Houben et al.,
2010b; Shuda et al., 2011). This data suggests that MCC tumor
cells are ‘addicted’ to the MCPyV T antigen proteins. But, is one T
antigen more oncogenic than the other? Is either T antigen
sufﬁcient for transformation? Many of the studies directed at
discerning a role for T antigens in MCPyV-induced transformation
have been complicated by the fact that all T antigens were
initially targeted for knockdown simultaneously through the use
of shRNAs speciﬁc to the common ﬁrst exon. While one report did
pinpoint a requirement for the pRb-binding motif in the ability of
LT to promote growth of MCPyV-positive MCC cell lines and
xenografts (Houben et al., 2012a), most of these studies could not
distinguish between the independent roles of LT and sT in
transformation. In 2011, Shuda and colleagues speciﬁcally tar-
geted sT with shRNA, and the individual oncogenic potential of
MCPyV LT and sT began to come into focus (Shuda et al., 2011). In
several different traditional in vitro transformation assays per-
formed in both rodent and human cells, sT exhibited an increased
transformation capacity compared to LT, which had very little
phenotype in these assays. Any transformation capacity of LT was
minimal compared to sT, although truncated LT showed more
proliferative capacity than full-length LT. Moreover, the sT trans-
formation activity was not enhanced by the presence of LT,
although this was only tested in one of many assays. These results
make an extremely convincing argument that sT is the dominant
MCPyV oncoprotein; however, the authors caution that sT alone
did not fully transform human cells and pose a reminder that
speciﬁc sT knockdown does not phenocopy knockdown of all T
antigens in MCC cell lines. So while this data suggests that LT
expression alone is not sufﬁcient for MCPyV-induced transforma-
tion, it appears necessary for optimal transformation by the
MCPyV T antigen locus. How these in vitro transformation
phenotypes relate to in vivo tumorigenicity properties of MCPyV
remains unclear.
The most widely characterized function of polyomavirus sT
antigens is the ability to bind and reprogram the cellular protein
phosphatase PP2A, a function that is intimately tied to its ability
to promote cell cycle progression and transformation (Reviewed
in Khalili et al., 2008; Pallas et al., 1990). Interestingly, mutational
disruption of the PP2A-binding site of MCPyV sT did not affect its
ability to promote transformation, which represents a major
departure from dogma on polyomavirus biology (Shuda et al.,
2011). Rather, sT was found to preserve hyperphosphorylation of
the cellular translation factor eIF4E-binding protein 1 (4E-BP1) in
an mTOR-dependent manner. Hyperphosphorylation of 4E-BP1
remained high in the presence of sT with a mutated PP2A-binding
site, suggesting this function of sT does not require sT:PP2A
association. This post-translational modiﬁcation was conﬁrmed
in four MCPyV-positive MCC cell lines and was abolished follow-
ing shRNA-mediated sT knockdown. The 4E-BP1 protein binds to
the cap-binding protein eIF4E, but upon phosphorylation liberates
eIF4E to participate in a rate-limiting step of cap-dependent
translation (Pause et al., 1994). That sT increases association of
eIF4E and another accessory factor, eIF4G, with the 50-methyl-7-
guanosine cap in cap-binding assays is consistent with its ability
to preserve 4E-BP1 hyperphosphorylation. It therefore seems
likely that sT promotes a favorable cellular environment for activecap-dependent translation. Most importantly, the ability of sT to
preserve 4E-BP1 phosphorylation, which occurs independent of
its association with PP2A, is necessary for its role in driving
cellular transformation. Given that sT is more frequently
expressed in MCC than LT, together with its transformation
capacity in vitro, it seems likely that MCPyV sT may play a more
dominant role than LT in MCPyV-mediated tumorigenicity.
Additional studies have added insight into other potential
mechanisms of MCPyV-induced carcinogenesis. For instance,
although Akt is phosphorylated in almost 90% of MCCs, this
modiﬁcation is not associated with MCPyV status and is not
affected by LT/sT antigen knockdown in MCPyV-positive MCCs
(Hafner et al., 2012). These results mirror those reported by Shuda
et al. showing that MCPyV sT interaction with PP2A did not
activate Akt (Shuda et al., 2011). Together, these data suggest that
MCPyV oncoproteins are not involved in promoting the high Akt
activation observed in MCC.
The general lack of p53 mutations in MCPyV-positive MCCs is
also noteworthy. As mentioned previously, p53 mutations that
bear signatures consistent with UV-B exposure have been
detected in MCC cell lines (Popp et al., 2002). However, this study
was conducted prior to discovery of MCPyV and thus the viral
status of these MCC cell lines is unclear. More recently, the status
of p53 was analyzed in both MCPyV-positive and MCPyV-negative
MCC tumors (Sihto et al., 2011). Interestingly, an inverse correla-
tion between p53 expression and viral DNA copy number was
observed, and only 7% of MCPyV-positive MCC tumors expressed
detectable p53. Moreover, any p53 mutations observed in MCCs
were almost exclusively detected in MCPyV-negative MCCs. These
ﬁndings suggest that aberrant expression of mutated p53 is most
likely not a major driver of MCPyV-associated tumorigenesis.
It remains unclear whether MCPyV is functioning to inactivate
the p53 pathway, thereby eliminating any selective advantage
that mutations in p53 might provide to MCPyV-positive MCCs.
Finally, Houben et al. recently described a MCPyV-positive
MCC cell line in which proliferation is completely unaffected by T
antigen knockdown (Houben et al., 2012b), which may suggest a
hit-and-run mechanism of transformation. The link between MCC
and ultraviolet exposure may also provide clues to viral patho-
genesis. For instance, the MCPyV non-coding regulatory region
can be activated in vitro by UV exposure, and human skin samples
exposed to solar simulated radiation exhibited a dose-dependent
increase in sT transcript levels (Mogha et al., 2010). Moreover, a
MCPyV-infected MCC cell line showed impaired DNA damage
repair and cell cycle arrest following exposure to UV radiation
that was subsequently linked to LT, suggesting the presence of the
virus affects normal repair mechanisms in cells exposed to UV
(Demetriou et al., 2012). Clearly, the ongoing study of this new
human tumor virus will generate valuable knowledge about the
pathogenesis of MCPyV-induced MCC.Conclusions and future perspectives
The biological and epidemiological characteristics of MCPyV
culminate in the following hypothetical model for MCPyV-
associated tumorigenesis (For more thorough reviews, see Bhatia
et al., 2011; Chang and Moore, 2012; Moore and Chang, 2010).
By all accounts, the virus is obtained during early childhood via
transmission by either fecal-oral, respiratory, or cutaneous routes
and results in a mostly asymptomatic primary infection. The virus is
maintained as part of the normal microﬂora of mainly the skin,
where it is chronically shed in the form of encapsidated virions.
Localized or systemic compromises to the immune system, brought
on by UV radiation, natural aging, AIDS, or drug-induced suppres-
sion of the immune system such as occurs in organ transplant
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lance and subsequent virus reactivation. At this point, at least two
mutational events occur that are critical steps in the proposed
model of MCPyV-induced carcinogenesis. One mutational event is
the integration of the viral genome into the host chromosome. The
exogenous forces responsible for this event have not yet been
determined, but hypotheses range from UV and ionizing radiation
exposure to a defect in the virus itself. Moreover, the question of
whether Merkel cells are in fact the cell type where this integration
occurs, or if another prominent cell type in the skin is targeted, has
not been answered. An additional event important in MCPyV-
induced carcinogenesis is mutation of the viral genome in a manner
that renders the virus unable to replicate. The most common
mutations occur in the carboxy terminus of LT, which generate a
truncated LT that lacks the helicase domain required for replication
yet preserve its oncogenic functions. Because essentially all MCPyV-
positive MCC tumors express truncated LT, it seems likely a strong
selective pressure is implemented for replication-defective viruses.
The exact order of these two events has not been directly tested or
elucidated. One could envision viral genome integration as the ﬁrst
event, which would lead to unlicensed DNA synthesis and provoca-
tion of a cellular response leading to cell death, and LT truncation as
the second event that prevents this replication and thereby protects
the nascent tumor cell from its deleterious effects. An alternative
scenario where LT truncations occur ﬁrst followed by viral genome
integration also seems possible. It has been shown that expression
of truncated LT leads to defective DNA repair and cell cycle arrest in
response to UV radiation (Demetriou et al., 2012). Consequentially,
this increase in genomic instability may promote integration of the
viral genome harboring mutated LT sequences. Regardless of the
sequence of events, persistent expression of truncated LT and sT
from the integrated MCPyV genome can inactivate pRb tumor
suppressor function and promote and/or deregulate cap-dependent
translation initiation, respectively. Ultimately, the cells in which
integration of a replication-defective MCPyV is successful become
addicted to viral oncogene expression and undergo clonal expan-
sion and neoplastic progression to cause development of MCC.
It should be noted that this hypothetical model might not be
exclusive to the development of MCC. The presence of MCPyV
DNA in a variety of other cancers has been evaluated since its link
to MCC was reported. Many such analyses have discounted a role
of MCPyV in some cancers, including mesotheliomas (Bhatia et al.,
2010c), hematolymphoid cancers (Shuda et al., 2009), melanomas
(Varga et al., 2009) and colon cancer (Campello et al., 2011).
However, for other cancers there are contradictory ﬁndings.
A great amount of conﬂicting information exists regarding the
role of MCPyV in the pathogenesis of chronic lymphocytic
leukemia (Reviewed in Chang and Moore, 2012). Additionally,
contradictory data also exists for the relationship between squa-
mous cell carcinoma (SCC) and MCPyV. Some groups report no
signiﬁcant association (Andres et al., 2010; Reisinger et al., 2010),
whereas others point to the presence of MCPyV DNA in 40% of
cutaneous SCCs, which signiﬁcantly correlates with MCPyV ser-
opositivity (Rollison et al., 2012), and to the presence of MCPyV
DNA in SCCs prior to the development of MCC (Kaibuchi-Noda
et al., 2011). Strikingly, Dworkin et. al. detected mutations within
exon 2 of nearly all MCPyV-positive SCCs, and these mutations
theoretically produce truncated LT (Dworkin et al., 2009). Another
report observed MCPyV at a high frequency in both basal cell and
squamous cell carcinomas (Kassem et al., 2009). Finally, a full-
length MCPyV genome (MCV-TKS) was isolated from a Kaposi’s
sarcoma that expresses a truncated LT reminiscent of isolates
detected in MCCs (Katano et al., 2009). In conclusion, MCC may
not be the end of the story for MCPyV and human cancers.
The discovery of MCPyV and its apparent contribution to MCC
serves to highlight the continued signiﬁcance of the polyomavirusand DNA tumor virus ﬁelds. The current renaissance of collective
interest in polyomavirus research and tumor virology, coupled
with continuous technical advances, has already stimulated the
discovery of new human viruses. Through the use of rolling-circle
ampliﬁcation, consensus PCR, and deep sequencing, six new
human polyomaviruses have been discovered since the isolation
of MCPyV in 2008 (Buck et al., 2012; Sauvage et al., 2011;
Schowalter et al., 2010; Scuda et al., 2011; Siebrasse et al., 2012;
van der Meijden et al., 2010). While most details of its molecular
virology are still being elucidated, it is clear that MCPyV is unique
within the Polyomaviridae family in many respects. Isolation of a
naturally occurring, intact MCPyV will certainly excite and expe-
dite the process of learning more about its life cycle, lytic infection,
and host range. These molecular details will help reconcile the
known mechanisms of MCC pathogenesis with the etiological role
of MCPyV in this human cancer. More thrilling, however, is the
inherent potential this new human polyomavirus has to expose
pre-existing, yet uncovered, molecular mechanisms involved in cell
biology, virology, and carcinogenesis.Acknowledgments
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